Evaluation of bioavailability, efficacy, and safety profile of doxorubicin-loaded solid lipid nanoparticles

Chen

Journal of Food and Drug Analysis

et al. 2017

241

104

Chemical and enzymatic barriers in the gastrointestinal (GI) tract hamper the oral delivery of many labile drugs. The GI epithelium also contributes to poor permeability for numerous drugs. Drugs with poor aqueous solubility have difficulty dissolving in the GI tract, resulting in low bioavailability. Nanomedicine provides an opportunity to improve the delivery efficiency of orally administered drugs. Solid lipid nanoparticles (SLNs) are categorized as a new generation of lipid nanoparticles consisting of a complete solid lipid matrix. SLNs used for oral administration offer several benefits over conventional formulations, including increased solubility, enhanced stability, improved epithelium permeability and bioavailability, prolonged half-life, tissue targeting, and minimal side effects. The nontoxic excipients and sophisticated material engineering of SLNs tailor the controllable physicochemical properties of the nanoparticles for GI penetration via mucosal or lymphatic transport. In this review, we highlight the recent progress in the development of SLNs for disease treatment. Recent application of oral SLNs includes therapies for cancers, central nervous system-related disorders, cardiovascular-related diseases, infection, diabetes, and osteoporosis. In addition to drugs that may be active cargos in SLNs, some natural compounds with pharmacological activity are also suitable for SLN encapsulation to enhance oral bioavailability. In this article, we systematically introduce the concepts and amelioration mechanisms of the nanomedical techniques for drug- and natural compound-loaded SLNs.

Section: Oral Delivery Of Slns For Treating Various Diseasesmentioning

confidence: 99%

Recent advances in oral delivery of drugs and bioactive natural products using solid lipid nanoparticles as the carriers

Chen

Journal of Food and Drug Analysis

et al. 2017

241

104

“…Here, certain differences between the size of particles obtained by AFM and DLS are due to the working principles of these characterization methods . It has been reported that the particle size can be reduced by increasing the shear rate, and larger particles are obtained with a low shear rate. ,− Thereby, at first, we used manual shaking (low shear rate) as the emulsification method to prepare JMP to analyze particles via optical microscopy (OM) and to determine whether it is possible to control the geometry by changing the selected variables.…”

Section: Resultsmentioning

confidence: 99%

Tadpole-Like Anisotropic Polymer/Lipid Janus Nanoparticles for Nose-to-Brain Drug Delivery: Importance of Geometry, Elasticity on Mucus-Penetration Ability

Okmen Altas,

Kalaycioglu,

Lifshiz-Simon

et al. 2024

Mol. Pharmaceutics

Asymmetric geometry (aspect ratio >1), moderate stiffness (i.e., semielasticity), large surface area, and low mucoadhesion of nanoparticles are the main features to reach the brain by penetrating across the nasal mucosa. Herein, a new application has been presented for the use of multifunctional Janus nanoparticles (JNPs) with controllable geometry and size as a noseto-brain (N2B) delivery system by changing proportions of Precirol ATO 5 and polycaprolactone compartments and other operating conditions. To bring to light the N2B application of JNPs, the results are presented in comparison with polymer and solid lipid nanoparticles, which are frequently used in the literature regarding their biopharmaceutical aspects: mucoadhesion and permeability through the nasal mucosa. The morphology and geometry of JPs were observed via cryogenic-temperature transmission electron microscopy images, and their particle sizes were verified by dynamic light scattering, atomic force microscopy, and scanning electron microscopy. Although all NPs showed penetration across the mucus barrier, the best increase in penetration was observed with asymmetric and semielastic JNPs, which have low interaction ability with the mucus layer. This study presents a new and promising field of application for a multifunctional system suitable for N2B delivery, potentially benefiting the treatment of brain tumors and other central nervous system diseases.

Journal of advanced Biomedical and Pharmaceutical Sciences

“…5), and indicates that VLP produced a diffraction pattern with multiple peaks. A relatively sharp peak was observed for Precirol ATO 5 one characteristic peak appeared at 20 2θ (42). The diffraction peaks for physical mixture were found to be broader, less intense and more diffused than that of pure VLP and Precirol ATO5.…”

Section: -Wide Angle X-ray Diffraction (Xrd)mentioning

confidence: 86%

Development and characterization of nanostructure lipid carrier for anti-hepatitis-C virus drug

EL-Badry,

Mahmoud,

Fathalla

et al. 2023

Velpatasvir (VLP) as, a medication used to treat hepatitis-C virus (HCV). It has a very low oral bioavailability (25%). The aim of the current work is to prepare VLP loaded nanostructured lipid carriers (VLP-NLCs) as a potential way to enhance VLP aqueous solubility and bioavailability and increase its efficacy. The preparation of VLP-NLCs was carried out using the emulsification -solvent evaporation method, followed by ultrasonication. The prepared nanocarrier was examined for its particle size, zeta potential, entrapment efficiency and in-vitro drug release of the selected formula. VLP-NLCs displayed narrow size distribution, spherical morphologies that were nanosized (105 ± 2.3 nm), and significant drug entrapment efficiencies (> 80%). Particle size ranged between 105 ± 2.3 to 1399 ± 2.8 nm and zeta potential between -14.6 ± 0.2 to -46.0 ± 1.1 mV. High entrapping efficiency was obtained due to incorporation of liquid lipid. The In Vitro release showed prolonged time dependent release. NLC 6 had the best results among the eight prepared formulae. These findings show that NLC is a potential carrier to improve the solubility of drug and enhance its bioavailability.